Extension Study of ASP015K - Open-Label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase IIb Study or Phase III Study of ASP015K.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Peficitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 10 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Aug 2017 Planned End Date changed from 30 Sep 2018 to 1 Sep 2018.
- 21 Aug 2017 Planned primary completion date changed from 30 Sep 2018 to 1 Sep 2018.